← Back to Search

Senolytic Agent

Senolytic Therapy for Chronic Kidney Disease

Phase 2
Waitlist Available
Led By LaTonya J Hickson, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-45 ml/min/1.73m2
Diabetes mellitus and taking diabetes medications
Must not have
New invasive cancer except non-melanoma skin cancers
Inability to tolerate oral medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 14, month 4, month 12
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether getting rid of senescent cells can help people with chronic kidney disease by reducing senescence burden, improving physical ability or frailty, and increasing mesenchymal stem cell functionality.

Who is the study for?
This trial is for adults aged 40-80 with chronic kidney disease (eGFR 15-45 ml/min/1.73m2) and diabetes on medication. Excluded are those with recent substance abuse, HIV, hepatitis B/C, pregnancy, certain heart conditions or allergies to the drugs tested, among other criteria.
What is being tested?
The study tests whether Dasatinib and Quercetin can reduce aging cells in patients with chronic kidney disease to improve physical function and stem cell health. Participants will be grouped to receive either drug combination.
What are the potential side effects?
Potential side effects of Dasatinib and Quercetin may include changes in blood counts leading to increased risk of infections or bleeding, nausea, diarrhea, muscle cramps, fatigue, fluid retention around the heart or lungs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is reduced, with an eGFR between 15-45.
Select...
I have diabetes and am on medication for it.
Select...
I am between 40 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a new cancer diagnosis that is not a non-melanoma skin cancer.
Select...
I cannot take medications by mouth.
Select...
I am currently on medication to suppress my immune system.
Select...
My weight is over 150 kg or my BMI is over 50.
Select...
I am not willing to stop my acid reflux medication for 3 weeks.
Select...
My lupus is not under control.
Select...
I have unmanaged fluid buildup in my chest or abdomen.
Select...
I am HIV positive.
Select...
I am unable to understand and give consent for treatment.
Select...
I am on a medication that targets cancer growth.
Select...
I have taken quinolone antibiotics in the last 10 days.
Select...
I am taking medication that strongly affects liver enzyme CYP3A4.
Select...
I do not have an active hepatitis B or C infection.
Select...
I have a kidney condition called glomerulonephritis.
Select...
I have an invasive fungal or viral infection.
Select...
I have been diagnosed with kidney artery disease.
Select...
I have a genetic form of polycystic kidney disease.
Select...
I have been diagnosed with nephrotic syndrome.
Select...
I have had a solid organ transplant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 14, month 4, month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 14, month 4, month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in proportion of senescent cells (representing the total senescent cell burden) present
Secondary study objectives
Change in Frailty index score
Change in kidney function
Change in mesenchymal stem cell function
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Group 1: ObservationalActive Control1 Intervention
Observational Only
Group II: Group 2: Dasatinib & QuercetinActive Control2 Interventions
The drugs dasatinib and quercetin will be used in this arm

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,353 Previous Clinical Trials
3,060,993 Total Patients Enrolled
LaTonya J Hickson, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
32 Total Patients Enrolled

Media Library

Dasatinib (Senolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT02848131 — Phase 2
Dasatinib (Senolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02848131 — Phase 2
Chronic Kidney Disease Clinical Trial 2023: Dasatinib Highlights & Side Effects. Trial Name: NCT02848131 — Phase 2
Chronic Kidney Disease Research Study Groups: Group 1: Observational, Group 2: Dasatinib & Quercetin
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top